TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03090906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue augmentation palate
Description: Recipient site: Intrasulcular incision at the buccal side of the implant extending in one adjacent tooth for each side and a partial-thickness mucosal ﬂap raised. The connective tissue was secured with suture. Allocation to either treatment was performed according to a randomization table.~Donor site A double-bladed scalpel handle 1,5mm was used in both areas to obtain the same thickness.~Palate (CG) The double incision was made approximately 2 to 3 mm apical to the gingival margins of premolars. The donor tissue was removed and cross-mattress sutures were used to approximate the wound on the palate.~In both groups the epithelial collar removed. Graft required dimensions for both groups:10mm height, 12mm length and 1,5mm thick.
Study: NCT01393093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Chemoembolization
Description: Transcatheter Arterial Chemoembolization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Chemoembolization
Description: Transcatheter Arterial Chemoembolization
Study: NCT00448292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-00023
Description: Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for PRX-00023
Description: Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
Study: NCT00682630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyronaridine artesunate clinical trial reference tablets
Description: Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyronaridine artesunate clinical trial reference tablets
Description: Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyronaridine artesunate to-be-marketed tablets
Description: Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyronaridine artesunate to-be-marketed tablets
Description: Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)
Study: NCT00924703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAvPAL-PEG
Description: The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.
Study: NCT03040154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Documentary entitled, Para Sa Kinabukasan ng Mga Anak (For Our Children's Future)
Study: NCT03090906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue augmentation tuberosity
Description: Recipient site: Intrasulcular incision at the buccal side of the implant extending in one adjacent tooth for each side and a partial-thickness mucosal ﬂap raised. The connective tissue was secured with suture. Allocation to either treatment was performed according to a randomization table.~Donor site A double-bladed scalpel handle 1,5mm was used in both areas to obtain the same thickness.~Tuberosity (TG) The double incision was made from the distal of the terminal tooth. A second incision was made perpendicular to the linear incision at a distal point, which joined the two linear incisions. The graft was removed and a crossed horizontal suspension suture was used.~Epithelial collar removed. Graft required dimensions for both groups:10mm height, 12mm length and 1,5mm thick.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral optical scan
Description: Intraoral optical scan was performed at both groups at baseline, 3 months, 4 months and 12 months to be able to compare volumetric changes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral optical scan
Description: Intraoral optical scan was performed at both groups at baseline, 3 months, 4 months and 12 months to be able to compare volumetric changes.
Study: NCT01253590

Intervention type: BEHAVIORAL
Intervention: questionnaire about the use of ECG device
Description: Patients will be fitted with a continuous ECG monitor and blood pressure device. Data on every heart beat, including episodes of atrial fibrillation, for 4-6 weeks of continuous monitoring will be collected and transmitted wirelessly. Based on this information and blood pressure readings performed by patients in their home setting, clinicians can adjust oral coagulant dosage. Participants will attend 2 follow-up outpatient visits at the MSKCC outpatient cardiology practice upon the cardiologist's recommendation. Upon completion of the study, 4-6 weeks, a questionnaire will be sent via mail, including a pre-paid envelope, to participants to assess feasibility, acceptance, and overall experience with remote cardiac monitoring.
Study: NCT00934934

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anidulafungin
Description: TBA
Study: NCT01049607

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clamp-Crush technique
Description: The transectional line is marked and the liver capsule is cauterized. The liver parenchyma is then crushed stepwise using a regular Pèan clamp. Vessels and bile ducts are ligated or clipped. Vessels of less than 2mm diameter are coagulated with the irrigated bipolar forceps.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stapler hepatectomy
Description: The transectional line is marked and the liver capsule is cauterized. For subsequent transection of the hepatic parenchyma, the liver tissue is fractured with a vascular clamp in a stepwise fashion and subsequently divided with endo GIA vascular staplers.
Study: NCT00781586

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350)
Description: One A Day Weight Smart Advanced 1 tablet at 1st visit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Caffeine 100 mg 1 tablet at 1st visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet at 1st visit
Study: NCT02363634

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: magnesium threonate
Description: nutritional product
Study: NCT03481998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole or anastrozole or Fulvestrant
Description: Letrozole 2.5mg or anastrozole 1mg, orally once daily (continuously)， or Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole or anastrozole or Fulvestrant
Description: Letrozole 2.5mg or anastrozole 1mg, orally once daily (continuously)， or Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole or anastrozole or Fulvestrant
Description: Letrozole 2.5mg or anastrozole 1mg, orally once daily (continuously)， or Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole or anastrozole or Fulvestrant
Description: Letrozole 2.5mg or anastrozole 1mg, orally once daily (continuously)， or Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole or anastrozole or Fulvestrant
Description: Letrozole 2.5mg or anastrozole 1mg, orally once daily (continuously)， or Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
Study: NCT03344055

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff Vision (ECV) second generation
Description: Colonoscopy performed with the use of Endocuff Vision (ECV) second generation at the tip of the scope
Study: NCT03956706

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Stereotactic radiosurgery dose escalation by either 18, 20, or 22 Gy to the subventricular zone in addition to standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Stereotactic radiosurgery dose escalation by either 18, 20, or 22 Gy to the subventricular zone in addition to standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Stereotactic radiosurgery dose escalation by either 18, 20, or 22 Gy to the subventricular zone in addition to standard of care
Study: NCT05709080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: family-professional collaboration practice model
Description: Online instructional sessions will be conducted in two sessions for six hours (3 hours per session) for the physical therapists in the experimental group. The instructional session focus on explaining the specific strategies and process to implement the Family-professional Collaboration (four step process) Model as ( Step 1: Mutually agreed-upon goals, Step 2: Shared planning, Step 3: Shared implementation and Step 4: Shared evaluation of child and family outcomes.
Study: NCT00407875

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity Modulated External Beam Radiation Therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated External Beam Radiation Therapy
Study: NCT00402233

Intervention type: DRUG
Group type: OTHER
Intervention: Pramipexole

Intervention type: DRUG
Group type: OTHER
Intervention: Pramipexole
Study: NCT03040154

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Video that is publicly available
Study: NCT00628355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: Women randomized for this treatment was submitted to 2mL of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point. Patients received lidocaine injections once a week for 4 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic compression
Description: Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation(TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
Study: NCT04580147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection
Description: Intravitreal aflibercept injection (2mg/0.05mL) at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: Sham procedure at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
Study: NCT00797121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative biliary drainage
Description: Percutaneous transhepatic biliary drainage(PTBD) is performed under the guidance of ultrasound. The duration may be around four weeks to make the total bilirubin of patients lower than 85μmol/L.
Study: NCT04144621

Intervention type: PROCEDURE
Intervention: ICSI
Description: Intracytoplasmic sperm injection of female partner oocytes with ejaculated sperm selected by density gradient centrifugation

Intervention type: PROCEDURE
Intervention: ICSI
Description: Intracytoplasmic sperm injection of female partner oocytes with ejaculated sperm selected by density gradient centrifugation
Study: NCT03971721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wave 4.3
Description: The Wave 4.3 mattress support is an insert, placed underneath the user's existing mattress, that when inflated increases the longitudinal incline of the mattress support, increasing in inclination in the direction of the head of the bed. The resulting mattress contours are such that the mattress has a lateral inclination of approximately 15 degrees in the head section and 10 degrees in the torso section. In addition to the features allowing the user to activate and deactivate creation of this Graduated Lateral RotationTM orientation, this device has sensors and monitoring system allowing for remotely monitoring the status of the system, including confirming that the supports are achieving the prescribed support angles, and that the system is working as planned.
Study: NCT04970667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flupentixol melitracen tablets
Description: Patients were treated with Flupentixol and melitracen tablets for 12 weeks
Study: NCT03912584

Intervention type: DEVICE
Group type: OTHER
Intervention: P200TE
Description: The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.

Intervention type: DEVICE
Group type: OTHER
Intervention: P200TxE
Description: The P200TxE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
Study: NCT01321489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate 20mg Tablet Sublingual
Description: Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viagra ® 50mg tablet Coated
Description: Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
Study: NCT03935516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cast
Description: The use of plaster and/or fiberglass for casting of subject arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cast
Description: The use of plaster and/or fiberglass for casting of subject arm.
Study: NCT01526356

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study cream is applied nightly to the affected areas on the face.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Study cream is applied nightly to the affected areas on the face. Low Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Study cream is applied nightly to the affected areas on the face. High Dose
Study: NCT01668368

Intervention type: OTHER
Group type: OTHER
Intervention: esophageal balloon
Description: esophageal pressure as a surrogate for pleural pressure
Study: NCT01236391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: 560 mg daily
Study: NCT02056678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen, IV preparation
Study: NCT02566005

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: 25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist).
Study: NCT00402233

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study: NCT03665818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral appliance treatment
Description: mandibular advancement device to enlarge pharyngeal airway space to get rid of apnea and hypopnea events
Study: NCT02483767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: Gonadotropin-Releasing Hormone Agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard chemotherapy
Description: (Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel; doxetaxel/cyclophosphamide; doxetaxel or paclitaxel/Anthracyclines; fluorouraci/Anthracyclines/cyclophosphamide followed by doxetaxel or paclitaxel; doxetaxel/Anthracyclines/cyclophosphamide; Anthracyclines/cyclophosphamide;
Study: NCT00670787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination pill of losartan and hydrochlorothiazide
Description: Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
Study: NCT01769105

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lipiflow
Description: Patients receive a single Lipiflow-treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lid hygiene regime
Description: Patients receive verbal and written instruction to perform lid hygiene twice daily
Study: NCT00105872

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive-Behavioral Therapy
Study: NCT03085784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: The investigational product is intravitreal aflibercept injection (IAI), which will be supplied by Regeneron Pharmaceuticals, Inc. in sterile vials for intravitreal (IVT) injection. The study duration will be 52 weeks. Vials of drug must be used (defined as entered with needle) only once. All drug supplies are to be kept under recommended storage conditions. The injection volume will be 50μL (0.05 mL) and will be administered to the patients by IVT injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: The investigational product is intravitreal aflibercept injection (IAI), which will be supplied by Regeneron Pharmaceuticals, Inc. in sterile vials for intravitreal (IVT) injection. The study duration will be 52 weeks. Vials of drug must be used (defined as entered with needle) only once. All drug supplies are to be kept under recommended storage conditions. The injection volume will be 50μL (0.05 mL) and will be administered to the patients by IVT injection.
Study: NCT02483767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard chemotherapy
Description: (Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel; doxetaxel/cyclophosphamide; doxetaxel or paclitaxel/Anthracyclines; fluorouraci/Anthracyclines/cyclophosphamide followed by doxetaxel or paclitaxel; doxetaxel/Anthracyclines/cyclophosphamide; Anthracyclines/cyclophosphamide;
Study: NCT02158559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danhong Injection
Description: Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
Study: NCT03148210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment strategy using evidence-based guidelines for asthma or COPD
Description: The respirologist will determine the clinical extent of the patient's symptoms, activity limitation, and degree of airflow obstruction and will commence the subject on asthma or COPD medications if indicated

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: Smoking cessation counselling by a qualified educator if currently smoking

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation
Description: Smoking cessation counselling by a qualified educator if currently smoking

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Participant Education
Description: Standardized education for asthma or COPD disease
Study: NCT02104037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Study: NCT02556164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Acupuncture is an alternative medicine methodology that treats patient by various techniques including inserting small, thin needles at specific points of body. Electroacupuncture (EA), like the name implies, combines classical acupuncture and low electric current running through the needles, which are often used to enhance a treatment.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture
Description: Acupuncture is an alternative medicine methodology that treats patient by various techniques including inserting small, thin needles at specific points of body. Electroacupuncture (EA), like the name implies, combines classical acupuncture and low electric current running through the needles, which are often used to enhance a treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body-worn sensor technology
Description: Three-dimensional acceleration and angular velocity of shanks, thighs and the trunk were measured using wearable sensors each included a triaxial accelerometer and a triaxial gyroscope (LEGSys™ and BalanSens™ - BioSensics, Boston, MA)
Study: NCT03011125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexlansoprazole injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo